Clinical Study

Pancreas Transplantation: Does Age Increase Morbidity?

Table 1

Patient characteristics and donor parameters.

<50 years of age
≥50 years of age
P value

Male, n (%)60 (50%)11 (65%).27
Recipient Age37 ± 7.054 ± 3.2<.0001
Body Mass Index (kg/m2)25.0 ± 5.026.1 ± 4.0.30
Age at diagnosis of type 1 DM (years)13 ± 6.521 ± 9.2.001
Duration of type 1 DM prior to transplant (years)24 ± 6.833 ± 9.0.0004
Preoperative Hemodialysis, n (%)99 (83%)13 (76%).50
HCV, n (%)5 (4%)0 (0%)1.0

Comorbidities:
Hypertension, n (%)60 (50%)9 (53%).85
Peripheral Vascular Disease, n (%)32 (27%)9 (53%).03
Coronary Artery Disease, n (%)21 (18%)8 (47%).006
Cerebrovascular Disease, n (%)3 (3%)2 (12%).12

Preoperative serum albumin (g/dl)3.80 ± 0.583.86 ± 0.64.98

CMV Status:
D+/R+, n (%)39 (33%)4 (24%)
D−/R+, n (%)19 (16%)3 (18%).90
D+/R−, n (%)31 (26%)5 (29%)
D−/R−, n (%)30 (25%)5 (29%)

SPK, n (%)81 (68%)11 (65%)  
PAK, n (%)31 (26%)6 (35%).47
PTA, n (%)7 (6%)0 (0%)

Enteric Drainage, n (%)100 (84%)16 (94%).47
Induction therapy used (yes), n (%)65 (55%)13 (77%).12

Induction Agent:
None, n (%)54 (45%)4 (23%)
IL-2RA, n (%)51 (43%)10 (59%).23
Antithymocyte Globulin, n (%)14 (12%)3 (18%)

Donor Age (years)30 ± 10.432 ± 10.7.52
Pancreas Cold Ischemia Time (hrs)7.8 ± 3.17.2 ± 3.8.52
HLA Mismatches4 ± 1.24 ± 1.8.41
Duration of follow-up (years)5.9 ± 4.54.8 ± 3.7.48

DM = Diabetes mellitus, D = Donor, R = Recipient, IL-2RA = Interleukin-2 Receptor Antagonist, HLA = Human Leukocyte Antigen.